Prostate Cancer Treatments

Find Prostate Cancer Treatments

Brand Name

Xtandi

Generic Name
Enzalutamide
View Brand Information
FDA approval date: August 31, 2012
Classification: Androgen Receptor Inhibitor
Form: Tablet, Capsule

What is Xtandi (Enzalutamide)?

XTANDI ® is indicated for the treatment of patients with: castration-resistant prostate cancer , metastatic castration-sensitive prostate cancer , non‑metastatic castration‑sensitive prostate cancer with biochemical recurrence at high risk for metastasis XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:, castration-resistant prostate cancer. , metastatic castration-sensitive prostate cancer. , non‑metastatic castration‑sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phas...

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2

Summary: The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant pros...

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Who is this study for: Adult patients with relapsed/refractory small cell lung cancer, castration-resistant prostate cancer and follicular lymphoma
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: PF-06821497
Study Phase: Phase 1

Summary: The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part...

View All Clinical Trials

Related Latest Advances

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
Journal: Future oncology (London, England)
Published: April 14, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.
Journal: The Journal of clinical investigation
Published: March 31, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026
View All Latest Advances